Erythrocyte-binding therapeutics
AssigneeEcole Polytechnique Federale De Lausanne (Epfl)
InventorsJeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
Life of this patent
Estimating the term…
Abstract
Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
Claims16
A pharmaceutically acceptable composition for inducing tolerance of an antigenic therapeutic protein comprising:
- a fusion molecule having an erythrocyte-binding moiety and a portion of the antigenic therapeutic protein,
- wherein said erythrocyte-binding moiety has the ability to non-covalently, specifically bind an exterior erythrocyte surface in situ in blood and
- wherein said antigenic therapeutic protein portion is a portion of human Factor VIII.
A pharmaceutically acceptable composition for inducing tolerance to a therapeutic protein in a subject having a deficiency in production of a functional native protein, comprising:
- a fusion molecule comprising an erythrocyte-binding moiety and a portion of the antigenic therapeutic protein,
- wherein said erythrocyte-binding moiety has the ability to non-covalently, bind an exterior surface of erythrocytes in situ in blood and does not specifically bind to other blood components,
- wherein said therapeutic protein is Factor VIII, and wherein the antigenic portion consists of a portion of human Factor VIII.
A pharmaceutically acceptable composition for inducing tolerance to a therapeutic protein in a subject having a deficiency in production of a functional native protein, comprising:
- a fusion molecule comprising an erythrocyte-binding moiety and an antigenic portion of the therapeutic protein,
- wherein said erythrocyte-binding moiety has the ability to non-covalently, bind an exterior surface of erythrocytes in situ in blood and does not specifically bind to other blood components,
- wherein the erythrocyte-binding moiety is a single-chain variable fragment (scFv) derived from 10F7 that targets glycophorin A on erythrocytes, wherein said therapeutic protein is Factor VIII, and wherein the antigenic portion of the Factor VIII comprises a portion of human Factor VIII.
Dependencies are inferred from the claim text.